TOKYO, May 12 (Pulse News Wire) – MEC Company Ltd. (4971.T) reported a revenue increase of 11% to ¥5.028 billion for the quarter ending June 2026 compared to the same period last year.
Operating profit rose by 50%, reaching ¥2.079 billion. The company's pharmaceutical sales grew by 21%, contributing significantly to overall performance. Additionally, shipment volumes increased by 10%.
Key products such as CZ, SF, EXE, and V-Bond saw respective growth rates of 20%, 15%, 10%, and 5%. Looking ahead, MEC anticipates continued demand driven by advancements in IoT, AI, 5G/6G technology, and electric vehicle trends. Specifically, the company expects robust semiconductor needs to fuel further expansion in its related markets, particularly in high-density packaging substrates.
For the fiscal year ending December 2026, MEC forecasts revenues of ¥20.21 billion and operating profits of ¥7.600 billion, representing increases of 10% and 15%, respectively, compared to the previous year.
🔴 Confidence: Review recommended AI-translated content.